LYEL
Lyell Immunopharma Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.
Market Cap: 671 Million
Primary Exchange: NASDAQ
Website: lyell.com
Shares Outstanding: 254 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 2.2595092416734097
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 781 trading days
From: 2021-09-10 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|